Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase

Sultan Darvesh, Katherine V. Darvesh, Robert S. McDonald, Diane Mataija, Ryan Walsh, Sam Mothana, Oksana Lockridge, Earl Martin

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Most carbamates are pseudoirreversible inhibitors of cholinesterases. Phenothiazine carbamates exhibit this inhibition of acetylcholinesterase but produce reversible inhibition of butyrylcholinesterase, suggesting that they do not form a covalent bond with the catalytic serine. This atypical inhibition is attributable to π-π interaction of the phenothiazine moiety with F329 and Y332 in butyrylcholinesterase. These residues are in a helical segment, referred to here as the E-helix because it contains E325 of the catalytic triad. The involvement of the E-helix in phenothiazine carbamate reversible inhibition of butyrylcholinesterase is confirmed using mutants of this enzyme at A328, F329, or Y332 that show typical pseudoirreversible inhibition. Thus, in addition to various domains of the butyrylcholinesterase active site gorge, such as the peripheral anionic site and the π-cationic site of the Ω-loop, the E-helix represents a domain that could be exploited for development of specific inhibitors to treat dementias.

Original languageEnglish (US)
Pages (from-to)4200-4212
Number of pages13
JournalJournal of Medicinal Chemistry
Volume51
Issue number14
DOIs
StatePublished - Jul 24 2008

Fingerprint

Butyrylcholinesterase
Carbamates
Acetylcholinesterase
Covalent bonds
Cholinesterase Inhibitors
Serine
Dementia
Catalytic Domain
Inhibition (Psychology)
Enzymes
phenothiazine

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Darvesh, S., Darvesh, K. V., McDonald, R. S., Mataija, D., Walsh, R., Mothana, S., ... Martin, E. (2008). Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. Journal of Medicinal Chemistry, 51(14), 4200-4212. https://doi.org/10.1021/jm8002075

Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. / Darvesh, Sultan; Darvesh, Katherine V.; McDonald, Robert S.; Mataija, Diane; Walsh, Ryan; Mothana, Sam; Lockridge, Oksana; Martin, Earl.

In: Journal of Medicinal Chemistry, Vol. 51, No. 14, 24.07.2008, p. 4200-4212.

Research output: Contribution to journalArticle

Darvesh, S, Darvesh, KV, McDonald, RS, Mataija, D, Walsh, R, Mothana, S, Lockridge, O & Martin, E 2008, 'Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase', Journal of Medicinal Chemistry, vol. 51, no. 14, pp. 4200-4212. https://doi.org/10.1021/jm8002075
Darvesh, Sultan ; Darvesh, Katherine V. ; McDonald, Robert S. ; Mataija, Diane ; Walsh, Ryan ; Mothana, Sam ; Lockridge, Oksana ; Martin, Earl. / Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. In: Journal of Medicinal Chemistry. 2008 ; Vol. 51, No. 14. pp. 4200-4212.
@article{cef3226552a84efc9db3bf73815929af,
title = "Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase",
abstract = "Most carbamates are pseudoirreversible inhibitors of cholinesterases. Phenothiazine carbamates exhibit this inhibition of acetylcholinesterase but produce reversible inhibition of butyrylcholinesterase, suggesting that they do not form a covalent bond with the catalytic serine. This atypical inhibition is attributable to π-π interaction of the phenothiazine moiety with F329 and Y332 in butyrylcholinesterase. These residues are in a helical segment, referred to here as the E-helix because it contains E325 of the catalytic triad. The involvement of the E-helix in phenothiazine carbamate reversible inhibition of butyrylcholinesterase is confirmed using mutants of this enzyme at A328, F329, or Y332 that show typical pseudoirreversible inhibition. Thus, in addition to various domains of the butyrylcholinesterase active site gorge, such as the peripheral anionic site and the π-cationic site of the Ω-loop, the E-helix represents a domain that could be exploited for development of specific inhibitors to treat dementias.",
author = "Sultan Darvesh and Darvesh, {Katherine V.} and McDonald, {Robert S.} and Diane Mataija and Ryan Walsh and Sam Mothana and Oksana Lockridge and Earl Martin",
year = "2008",
month = "7",
day = "24",
doi = "10.1021/jm8002075",
language = "English (US)",
volume = "51",
pages = "4200--4212",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase

AU - Darvesh, Sultan

AU - Darvesh, Katherine V.

AU - McDonald, Robert S.

AU - Mataija, Diane

AU - Walsh, Ryan

AU - Mothana, Sam

AU - Lockridge, Oksana

AU - Martin, Earl

PY - 2008/7/24

Y1 - 2008/7/24

N2 - Most carbamates are pseudoirreversible inhibitors of cholinesterases. Phenothiazine carbamates exhibit this inhibition of acetylcholinesterase but produce reversible inhibition of butyrylcholinesterase, suggesting that they do not form a covalent bond with the catalytic serine. This atypical inhibition is attributable to π-π interaction of the phenothiazine moiety with F329 and Y332 in butyrylcholinesterase. These residues are in a helical segment, referred to here as the E-helix because it contains E325 of the catalytic triad. The involvement of the E-helix in phenothiazine carbamate reversible inhibition of butyrylcholinesterase is confirmed using mutants of this enzyme at A328, F329, or Y332 that show typical pseudoirreversible inhibition. Thus, in addition to various domains of the butyrylcholinesterase active site gorge, such as the peripheral anionic site and the π-cationic site of the Ω-loop, the E-helix represents a domain that could be exploited for development of specific inhibitors to treat dementias.

AB - Most carbamates are pseudoirreversible inhibitors of cholinesterases. Phenothiazine carbamates exhibit this inhibition of acetylcholinesterase but produce reversible inhibition of butyrylcholinesterase, suggesting that they do not form a covalent bond with the catalytic serine. This atypical inhibition is attributable to π-π interaction of the phenothiazine moiety with F329 and Y332 in butyrylcholinesterase. These residues are in a helical segment, referred to here as the E-helix because it contains E325 of the catalytic triad. The involvement of the E-helix in phenothiazine carbamate reversible inhibition of butyrylcholinesterase is confirmed using mutants of this enzyme at A328, F329, or Y332 that show typical pseudoirreversible inhibition. Thus, in addition to various domains of the butyrylcholinesterase active site gorge, such as the peripheral anionic site and the π-cationic site of the Ω-loop, the E-helix represents a domain that could be exploited for development of specific inhibitors to treat dementias.

UR - http://www.scopus.com/inward/record.url?scp=47749102491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749102491&partnerID=8YFLogxK

U2 - 10.1021/jm8002075

DO - 10.1021/jm8002075

M3 - Article

C2 - 18570368

AN - SCOPUS:47749102491

VL - 51

SP - 4200

EP - 4212

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -